Cordant Inc’s Myriad Genetics MYGN Stock Holding History

Cordant Inc’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5	Closed	–	–	829
2022 Q1	$0	Buy	+5	New	+$128	﹤0.01%	1328

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cordant Inc's MYGN Position: Q2 2022 in Review

Cordant Inc sold out of Myriad Genetics (MYGN) in Q2 2022, closing a stake of 5 shares.

Cordant Inc first reported a position in MYGN in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 198 funds tracked by Wall St. Rank hold MYGN as of Q2 2022.

Cordant Inc reported no remaining Myriad Genetics position as of Q2 2022 after selling out during the quarter.
Cordant Inc sold 5 Myriad Genetics shares in Q2 2022.
Cordant Inc first reported a position in Myriad Genetics in Q1 2022 and held it in 1 quarter.
Cordant Inc's Myriad Genetics position peaked at $0 in Q1 2022.
198 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2022.

Based on Cordant Inc's 13F filing for Q2 2022, filed 17 Aug 2022.